Related Experiment Videos
Anecortave acetate for treating or preventing choroidal neovascularization
1Department of Ophthalmology, New York University School of Medicine, 530 First Avenue, New York, NY 10016, USA. jslakter@aol.com
Ophthalmology Clinics of North America
|August 29, 2006
Summary
Current treatments for advanced Age-related Macular Degeneration (AMD) do not halt progression. Anecdotally, anecortave acetate shows promise in slowing early-stage AMD, preserving sight and reducing societal costs.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Advanced Age-related Macular Degeneration (AMD) treatments are available but do not halt disease progression.
- Progression of dry AMD to choroidal neovascularization (CNV) in one eye poses a significant risk to the other eye.
- Currently, no approved therapies exist to halt the progression of early-stage AMD, highlighting a critical unmet need.
Purpose of the Study:
- To evaluate anecortave acetate as a prophylactic treatment to slow the progression of early-stage AMD.
- To assess the safety and efficacy of anecortave acetate in preventing CNV growth.
- To explore the potential economic and quality-of-life benefits of early AMD intervention.
Main Methods:
- Ongoing clinical trials are investigating the role of anecortave acetate.
- Completed studies have analyzed its mechanism of action against CNV growth.
- Dosing intervals suitable for prophylactic therapy were assessed for safety.
Main Results:
- Anecdotally, anecortave acetate demonstrated a mechanism of action that decreases CNV growth.
- The drug's dosing interval supports its use in prophylactic therapy.
- Clinical studies indicated that anecortave acetate is safe for patient use.
Conclusions:
- Anecdotally, anecortave acetate shows potential as a prophylactic treatment for early AMD.
- Its safety profile and mechanism against CNV growth are promising.
- Early intervention with such agents could lead to significant societal cost savings and improved patient quality of life.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...